Nashville Biosciences
Elizabeth Ann Stringer has a diverse work background in scientific research and data analysis. Elizabeth Ann is currently serving as the Chief Scientific Officer at Nashville Biosciences since July 2020. Prior to that, they held the position of Chief Science Officer at axialHealthcare from November 2013 to August 2019, where they led the data science and analytics teams in research, development, analysis, and reporting of client data.
Before joining axialHealthcare, Stringer worked as a Postdoctoral Research Fellow at Stanford University School of Medicine from March 2011 to June 2013. In this role, they assisted Dr. Jarred Younger in establishing and running the Adult and Pediatric Pain Laboratory and managed six scientific studies, which involved overseeing study designs, participant recruitment, data acquisition, and analysis.
Elizabeth Ann'searlier experience includes working as a Doctoral Candidate at Vanderbilt University from August 2004 to November 2010, where they focused on optimizing human MRI at 7 Telsa. Elizabeth Ann managed three scientific studies, wrote grant proposals and manuscripts, and presented major findings at numerous conferences locally, nationally, and internationally.
Stringer also gained research experience as a Research Assistant at The National High Magnetic Field Laboratory in 2002, where they assisted in data collection and analysis in the condensed matter group.
Overall, Elizabeth Ann Stringer's work experience showcases their expertise in leading scientific research teams, conducting data analysis, managing projects, and presenting research findings.
Elizabeth Ann Stringer attended The University of the South from 1999 to 2003, where they obtained a Bachelor of Science (B.S.) degree in Physics. Following that, they pursued further education at Vanderbilt University School of Medicine from 2004 to 2010, earning a Ph.D. in Neuroimaging.
Nashville Biosciences
Nashville Biosciences, a wholly owned subsidiary of Vanderbilt University Medical Center, was created to harness the medical center's extensive genomic and bioinformatics resources for drug and diagnostics discovery and development. Leveraging Vanderbilt University Innovation™, Nashville Biosciences serves as a commercial interface between outside companies and the formidable research capabilities housed within Vanderbilt University Medical Center, including BioVU®, one of the world’s most comprehensive genetic databases linked to de-identified medical records with years of longitudinal clinical data. This unique asset is one of the largest and highest quality of its kind, providing an unprecedented opportunity to guide R&D activity in biotech, pharma, diagnostics, medical devices and other life sciences applications.